Publications

MM-398

A.C. Roy, S.R. Park, D. Cunningham, Y.K. Kang, Y. Chao, L.T. Chen, C. Rees, H.Y. Lim, J. Tabernero, F.J. Ramos, M. Kujundzic, M.B. Cardic, C.G. Yeh, & de. Gramont. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. 2013. Annals of Oncology. 2013 Feb 13; 00; 1-7, 2013. doi:10.1093/annonc/mdt002.

MM-121

Sheng, Q., Liu, X., Fleming, E., Yuan, K., Piao, H., Chen, J., Moustafa, Z., Thomas, R.K., Greulich, H., Schinzel, A., Zaghlul, S., Batt, D., Ettenberg, S., Meyerson, M., Schoeberl, B., Kung, A.L., Hahn, W.C., Drapkin, R., Livingston, D.M., and Liu, J,F. An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells. 2010. Cancer Cell. 2010 Mar 16;17(3):217-8.

Schoeberl, B., Faber, A., Li, D., Liang, M., Crosby, K., Onsum, M., Burenkova, O., Pace, E.A., Walton, Z., Nie, L., Fulgham, A., Song, Y., Nielsen., N., Engelman, J., and Kowk-Kin Wong. An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation. 2010. Cancer Research. 9 March 2010; 70(6):2485-94.

Schoeberl, B., Pace, E.A, Fitzgerald, J.B., Harms, B.D., Xu, L., Nie, L., Linggi, B., Kalra, A., Paragas, V., Bukhalid, R., Grantcharova, V., Kohli, N., West, K.A., Leszczyniecka, M., Feldhaus, M.J., Kudla, A.J., and Ulrik. B. Nielsen. Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis. 2009. Science Signaling. 30 June 2009; Volume 2, Issue 77, ra31.

MM-111

McDonagh, C., Huhalov, A., Harms, B., Adams, S., Paragas, V., Oyama S., Zhang, B., Luus, L., Overland, R., Nguyen, S., Gu, J., Kohli, N., Wallace, M., Feldhaus, M., Kudla, A., Schoeberl, B., and Nielsen, U. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Molecular Cancer Therapeutics, in press. January 16, 2012; doi: 10.1158/1535-7163.MCT-11-0820

MM-302

Reynolds JG, Geretti E, Hendriks BS, Lee H, Leonard SC, Noble CO, Lucker PB, Drummond DC, Olivier KJ Jr, Nielsen UB, Niyikiza C, Agresta SV, Wickham TJ. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol Apply Pharmacol. 2012 Jul 1; 262 (1): 1-10. doi:10.1016/j.taap.2012.04.008. Epub 2012 Apr 21.

MM-141

Xu L, Kohli N., Rennard R, Jiao Y, Razlog M, Zhang K, Baum J, Johnson B, Tang J, Schoeberl B, Fitzgerald J, Nielsen U, Lugovskoy A. Rapid optimization and prototyping for therapeutic antibody-like molecules. MAbs. 2013 Feb 7; 5 (2).  PMID: 23392215. (PubMed - as supplied publisher) 

Systems Biology

Harms, B., Kearns, J., Iadevaia, S., Lugovskoy, A.  Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies. 2013. Science Signaling. 18 July 2013.

Yaffe, M.B. The Scientific Drunk and the Lamppost: Massive Sequencing Efforts in Cancer Discovery and Treatment. 2013. Science Signaling. 6, pe13. **Non-Merrimack Featured Paper

Fitzgerald, J., and Lugovskoy, A. Rational Engineering of Antibody Therapeutics Targeting Multiple Oncogene Pathways. 2011. MAbs. 2011 May-Jun; 3(3): 299–309.

Chen, W.W., Schoeberl, B., Jasper, P.J., Niepel, M., Nielsen, U.B., Lauffenburger, D.A., and Peter K Sorger. Input-Output Behavior of ErbB Signaling Pathways as Revealed by a Mass Action Model Trained Against Dynamic Data. 2009. Molecular Systems Biology. 20 January 2009;doi:10.1038/msb.2008.74.

Schoeberl, B., Nielsen, U.B., and Riccardo Paxson.  Model-based Design Approaches in Drug Discovery: A Parallel to Traditional Engineering Approaches 2006. IBM Journal of Research and Development. November;50(6):645.

Fitzgerald, J.B., Schoeberl, B., Nielsen, U.B., and Peter K. Sorger.  Systems Biology and Combination Therapy in the Quest for Clinical Efficacy 2006. Nature Chemical Biology. September;2(9):458-66.

Janes, K.A., Gaudet, S., Albeck, J.G., Nielsen, U.B., Lauffenburger, D.A., and Peter K. Sorger.  The Response of Human Epithelial Cells to TNF Involves an Inducible  Autocrine Cascade. 2006. Cell. March;24(124):1225-1239.

Nielsen, U.B. and Birgit Schoeberl. Using Computational Modeling to Drive the Development of Targeted Therapeutics. 2005. IDrugs. Oct;8(10):822-6.

Gaudet, S., Janes, K.A., Albeck, J.G., Pace, E.A., Lauffenburger, D.A., and Peter K. Sorger. A Compendium of Signals and Responses Triggered by Prodeath and Prosurvival Cytokines. 2005. Mol Cell Proteomics.

Hornberg JJ, Binder B, Bruggeman FJ, Schoeberl B, Heinrich R., and Hans V. Westerhoff. Control of MAPK Signalling: from Complexity to What Really Matters. 2005. Oncogene: 24(36):5533-42.

Nielsen, U.B. and Bernhard H. Geierstanger. Multiplexed Sandwich Assays in Microarray Format. 2004. Journal of Immunological Methods: 290(1-2):170-120.

Nielsen, U.B., Cardone, M.H., Sinskey, A.J., MacBeath, G., and Peter K. Sorger. Profiling Receptor Tyrosine Kinase Activation By Using Ab Microarrays. 2003. PNAS: 100(16):9330-9335.

Schoeberl, B., Eichler-Jonsson, C., Dieter Gilles, E., and Gertraud Müller. Computational Modeling of the Dynamics of the MAP Kinase Cascade Activated by Surface and Internalized EGF Receptors 2002 Nature Biotechnology: 20.

Related Content

MM-398 MM-121 MM-111 MM-302 MM-141